Oncolytic virotherapies for pediatric tumors

References

• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi: 10.3322/caac.21654
   PubMed Web of Science ®Google Scholar
• Zhou X, Liao X, Zhang B, et al. Recurrence patterns in patients with high-grade glioma following temozolomide-based chemoradiotherapy. Mol Clin Oncol. 2016;5(2):289–294. doi: 10.3892/mco.2016.936
   PubMedGoogle Scholar
• Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010;362(23):2202–2211. doi: 10.1056/NEJMra0804577
   PubMed Web of Science ®Google Scholar
• Plant-Fox AS, O’Halloran K, Goldman S. Pediatric brain tumors: the era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae. Curr Probl Cancer. 2021;45(4):100777. doi: 10.1016/j.currproblcancer.2021.100777
   PubMed Web of Science ®Google Scholar
• Foreman PM, Friedman GK, Cassady KA, et al. Oncolytic virotherapy for the treatment of malignant glioma. Neurotherapeutics. 2017;14(2):333–344. doi: 10.1007/s13311-017-0516-0
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li Y, Chen K, et al. Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy. Cancer Cell Int. 2021;21(1):262. doi: 10.1186/s12935-021-01972-2
   PubMed Web of Science ®Google Scholar
• Lawler SE, Speranza MC, Cho CF, et al. Oncolytic viruses in cancer treatment: a review. JAMA Oncol. 2017;3(6):841–849. doi: 10.1001/jamaoncol.2016.2064
   PubMed Web of Science ®Google Scholar
• Lan Q, Xia S, Wang Q, et al. Development of oncolytic virotherapy: from genetic modification to combination therapy. Front Med. 2020;14(2):160–184. doi: 10.1007/s11684-020-0750-4
   PubMed Web of Science ®Google Scholar
• Alberts P, Tilgase A, Rasa A, et al. The advent of oncolytic virotherapy in oncology: the rigvir® story. Eur J Pharmacol. 2018;837:117–126. doi: 10.1016/j.ejphar.2018.08.042
   PubMed Web of Science ®Google Scholar
• Liang LM. Oncorine, the world first oncolytic virus medicine and its update in China. Curr Cancer Drug Targets. 2018;18(2):171–176. doi: 10.2174/1568009618666171129221503
   PubMed Web of Science ®Google Scholar
• Aguilar LK, Guzik BW, Aguilar-Cordova E. Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development. J Cell Biochem. 2011;112(8):1969–1977. doi: 10.1002/jcb.23126
   PubMed Web of Science ®Google Scholar
• Majem M, Cascallo M, Bayo-Puxan N, et al. Control of E1A under an E2F-1 promoter insulated with the myotonic dystrophy locus insulator reduces the toxicity of oncolytic adenovirus Ad-Delta24RGD. Cancer Gene Ther. 2006;13(7):696–705. doi: 10.1038/sj.cgt.7700940
   PubMed Web of Science ®Google Scholar
• Fueyo J, Alemany R, Gomez-Manzano C, et al. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst. 2003;95(9):652–660. doi: 10.1093/jnci/95.9.652
   PubMed Web of Science ®Google Scholar
• Garcia-Moure M, Martinez-Velez N, Gonzalez-Huarriz M, et al. The oncolytic adenovirus VCN-01 promotes anti-tumor effect in primitive neuroectodermal tumor models. Sci Rep. 2019;9(1):14368. doi: 10.1038/s41598-019-51014-1
   PubMedGoogle Scholar
• Wang P, Li X, Wang J, et al. Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent. Nat Commun. 2017;8(1):1395. doi: 10.1038/s41467-017-01385-8
   PubMedGoogle Scholar
• Mineta T, Rabkin SD, Yazaki T, et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med. 1995;1(9):938–943. doi: 10.1038/nm0995-938
   PubMed Web of Science ®Google Scholar
• Streby KA, Geller JI, Currier MA, et al. Intratumoral injection of HSV1716, an oncolytic herpes virus, is safe and shows evidence of immune response and viral replication in young cancer patients. Clin Cancer Res Off J Am Assoc Cancer Res. 2017;23(14):3566–3574. doi: 10.1158/1078-0432.CCR-16-2900
   PubMed Web of Science ®Google Scholar
• Kim JH, Oh JY, Park BH, et al. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther J Am Soc Gene Ther. 2006;14(3):361–370. doi: 10.1016/j.ymthe.2006.05.008
   PubMed Web of Science ®Google Scholar
• Kicielinski KP, Chiocca EA, Yu JS, et al. Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults. Mol Ther J Am Soc Gene Ther. 2014;22(5):1056–1062. doi: 10.1038/mt.2014.21
   PubMed Web of Science ®Google Scholar
• Gromeier M, Lachmann S, Rosenfeld MR, et al. Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc Natl Acad Sci U S A. 2000;97(12):6803–6808. doi: 10.1073/pnas.97.12.6803
   PubMed Web of Science ®Google Scholar
• Dingli D, Peng KW, Harvey ME, et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood. 2004;103(5):1641–1646. doi: 10.1182/blood-2003-07-2233
   PubMed Web of Science ®Google Scholar
• Yu L, Baxter PA, Zhao X, et al. A single intravenous injection of oncolytic picornavirus SVV-001 eliminates medulloblastomas in primary tumor-based orthotopic xenograft mouse models. Neuro Oncol. 2011;13(1):14–27. doi: 10.1093/neuonc/noq148
   PubMed Web of Science ®Google Scholar
• Kieran MW, Goumnerova L, Manley P, et al. Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma. Neuro Oncol. 2019;21(4):537–546. doi: 10.1093/neuonc/noy202
   PubMed Web of Science ®Google Scholar
• Ruano D, López-Martín JA, Moreno L, et al. First-in-human, first-in-child trial of autologous MSCs carrying the oncolytic virus icovir-5 in patients with advanced tumors. Mol Ther J Am Soc Gene Ther. 2020;28(4):1033–1042. doi: 10.1016/j.ymthe.2020.01.019
   PubMed Web of Science ®Google Scholar
• Gállego Pérez-Larraya J, Garcia-Moure M, Labiano S, et al. Oncolytic DNX-2401 virus for pediatric diffuse intrinsic pontine glioma. N Engl J Med. 2022;386(26):2471–2481. doi: 10.1056/NEJMoa2202028
   PubMed Web of Science ®Google Scholar
• Friedman GK, Johnston JM, Bag AK, et al. Oncolytic HSV-1 G207 immunovirotherapy for pediatric high-grade gliomas. N Engl J Med. 2021;384(17):1613–1622. doi: 10.1056/NEJMoa2024947
   PubMed Web of Science ®Google Scholar
• Cripe TP, Ngo MC, Geller JI, et al. Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients. Mol Ther J Am Soc Gene Ther. 2015;23(3):602–608. doi: 10.1038/mt.2014.243
   PubMed Web of Science ®Google Scholar
• Kolb EA, Sampson V, Stabley D, et al. A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a children’s oncology group Phase I consortium report. Pediatr Blood Cancer. 2015;62(5):751–758. doi: 10.1002/pbc.25464
   PubMed Web of Science ®Google Scholar
• Burke MJ, Ahern C, Weigel BJ, et al. Phase I trial of Seneca valley virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the children’s oncology group. Pediatr Blood Cancer. 2015;62(5):743–750. doi: 10.1002/pbc.25269
   PubMed Web of Science ®Google Scholar
• Vera B, Martínez-Vélez N, Xipell E, et al. Characterization of the Antiglioma Effect of the Oncolytic Adenovirus VCN-01. PLoS One. 2016;11(1):e0147211. doi: 10.1371/journal.pone.0147211
   PubMed Web of Science ®Google Scholar
• Martínez-Vélez N, Xipell E, Vera B, et al. The oncolytic adenovirus VCN-01 as therapeutic approach against pediatric osteosarcoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2016;22(9):2217–2225. doi: 10.1158/1078-0432.CCR-15-1899
   PubMed Web of Science ®Google Scholar
• Pascual-Pasto G, Bazan-Peregrino M, Olaciregui NG, et al. Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01. Sci Transl Med. 2019;11(476):eaat9321. doi: 10.1126/scitranslmed.aat9321
   PubMed Web of Science ®Google Scholar
• Bortolanza S, Bunuales M, Otano I, et al. Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters. Mol Ther J Am Soc Gene Ther. 2009;17(4):614–622. doi: 10.1038/mt.2009.9
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhang C, Miao J, et al. A tumor-targeted replicating oncolytic adenovirus Ad-TD-nsIL12 as a promising therapeutic agent for human esophageal squamous cell carcinoma. Cells. 2020;9(11):2438. doi: 10.3390/cells9112438
   PubMed Web of Science ®Google Scholar
• Studebaker AW, Hutzen BJ, Pierson CR, et al. Oncolytic herpes virus rRp450 shows efficacy in orthotopic xenograft group 3/4 medulloblastomas and atypical teratoid/rhabdoid tumors. Mol Ther Oncolytics. 2017;6:22–30. doi: 10.1016/j.omto.2017.05.005
   PubMed Web of Science ®Google Scholar
• Friedman GK, Moore BP, Nan L, et al. Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses. Neuro Oncol. 2016;18(2):227–235. doi: 10.1093/neuonc/nov123
   PubMed Web of Science ®Google Scholar
• Lun X, Ruan Y, Jayanthan A, et al. Double-deleted vaccinia virus in virotherapy for refractory and metastatic pediatric solid tumors. Mol Oncol. 2013;7(5):944–954. doi: 10.1016/j.molonc.2013.05.004
   PubMed Web of Science ®Google Scholar
• Komorowski M, Tisonczyk J, Kolakowska A, et al. Modulation of the tumor microenvironment by CXCR4 antagonist-armed viral oncotherapy enhances the antitumor efficacy of dendritic cell vaccines against neuroblastoma in syngeneic mice. Viruses. 2018;10(9):455. doi: 10.3390/v10090455
   PubMed Web of Science ®Google Scholar
• Ge Y, Wang H, Ren J, et al. Oncolytic vaccinia virus delivering tethered IL-12 enhances antitumor effects with improved safety. J Immunother Cancer. 2020;8(1):e000710. doi: 10.1136/jitc-2020-000710
   PubMed Web of Science ®Google Scholar
• Ma J, Jin C, Čančer M, et al. Concurrent expression of HP-NAP enhances antitumor efficacy of oncolytic vaccinia virus but not for Semliki Forest virus. Mol Ther Oncolytics. 2021;21:356–366. doi: 10.1016/j.omto.2021.04.016
   PubMed Web of Science ®Google Scholar
• Gujar SA, Clements D, Dielschneider R, et al. Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms. Br J Cancer. 2014;110(1):83–93. doi: 10.1038/bjc.2013.695
   PubMed Web of Science ®Google Scholar
• Kemp V, van den Wollenberg DJM, Camps MGM, et al. Arming oncolytic reovirus with GM-CSF gene to enhance immunity. Cancer Gene Ther. 2019;26(9–10):268–281. doi: 10.1038/s41417-018-0063-9
   PubMed Web of Science ®Google Scholar
• Toyoda H, Yin J, Mueller S, et al. Oncolytic treatment and cure of neuroblastoma by a novel attenuated poliovirus in a novel poliovirus-susceptible animal model. Cancer Res. 2007;67(6):2857–2864. doi: 10.1158/0008-5472.CAN-06-3713
   PubMed Web of Science ®Google Scholar
• Toyoda H, Wimmer E, Cello J. Oncolytic poliovirus therapy and immunization with poliovirus-infected cell lysate induces potent antitumor immunity against neuroblastoma in vivo. Int J Oncol. 2011;38(1):81–87. doi: 10.3892/ijo_00000826
   PubMed Web of Science ®Google Scholar
• Studebaker AW, Kreofsky CR, Pierson CR, et al. Treatment of medulloblastoma with a modified measles virus. Neuro Oncol. 2010;12(10):1034–1042. doi: 10.1093/neuonc/noq057
   PubMed Web of Science ®Google Scholar
• Studebaker AW, Hutzen B, Pierson CR, et al. Oncolytic measles virus efficacy in murine xenograft models of atypical teratoid rhabdoid tumors. Neuro Oncol. 2015;17(12):1568–1577. doi: 10.1093/neuonc/nov058
   PubMed Web of Science ®Google Scholar
• Lal S, Carrera D, Phillips JJ, et al. An oncolytic measles virus-sensitive Group 3 medulloblastoma model in immune-competent mice. Neuro Oncol. 2018;20(12):1606–1615. doi: 10.1093/neuonc/noy089
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhao X, Mao H, et al. Intravenous injection of oncolytic picornavirus SVV-001 prolongs animal survival in a panel of primary tumor-based orthotopic xenograft mouse models of pediatric glioma. Neuro Oncol. 2013;15(9):1173–1185. doi: 10.1093/neuonc/not065
   PubMed Web of Science ®Google Scholar
• Mennechet FJD, Paris O, Ouoba AR, et al. A review of 65 years of human adenovirus seroprevalence. Expert Rev Vaccines. 2019;18(6):597–613. doi: 10.1080/14760584.2019.1588113
   PubMed Web of Science ®Google Scholar
• Paielli DL, Wing MS, Rogulski KR, et al. Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse. Mol Ther J Am Soc Gene Ther. 2000;1(3):263–274. doi: 10.1006/mthe.2000.0037
   PubMed Web of Science ®Google Scholar
• Zhu J, Huang X, Yang Y. Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways. J Virol. 2007;81(7):3170–3180. doi: 10.1128/JVI.02192-06
   PubMed Web of Science ®Google Scholar
• Suzuki M, Cela R, Bertin TK, et al. NOD2 signaling contributes to the innate immune response against helper-dependent adenovirus vectors independently of MyD88 in vivo. Hum Gene Ther. 2011;22(9):1071–1082. doi: 10.1089/hum.2011.002
   PubMed Web of Science ®Google Scholar
• Minamitani T, Iwakiri D, Takada K. Adenovirus virus-associated RNAs induce type I interferon expression through a RIG-I-mediated pathway. J Virol. 2011;85(8):4035–4040. doi: 10.1128/JVI.02160-10
   PubMed Web of Science ®Google Scholar
• Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature. 2000;406(6797):782–787. doi: 10.1038/35021228
   PubMed Web of Science ®Google Scholar
• Fausther-Bovendo H, Kobinger GP. Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what’s important? Hum Vaccines Immunother. 2014;10(10):2875–2884. doi: 10.4161/hv.29594
   PubMed Web of Science ®Google Scholar
• Tang J, Olive M, Pulmanausahakul R, et al. Human CD8+ cytotoxic T cell responses to adenovirus capsid proteins. Virology. 2006;350(2):312–322. doi: 10.1016/j.virol.2006.01.024
   PubMed Web of Science ®Google Scholar
• Leen AM, Sili U, Vanin EF, et al. Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cells. Blood. 2004;104(8):2432–2440. doi: 10.1182/blood-2004-02-0646
   PubMed Web of Science ®Google Scholar
• Alonso MM, Cascallo M, Gomez-Manzano C, et al. ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo. Cancer Res. 2007;67(17):8255–8263. doi: 10.1158/0008-5472.CAN-06-4675
   PubMed Web of Science ®Google Scholar
• Stanelle J, Stiewe T, Theseling CC, et al. Gene expression changes in response to E2F1 activation. Nucleic Acids Res. 2002;30(8):1859–1867. doi: 10.1093/nar/30.8.1859
   PubMed Web of Science ®Google Scholar
• Rincón E, Cejalvo T, Kanojia D, et al. Mesenchymal stem cell carriers enhance antitumor efficacy of oncolytic adenoviruses in an immunocompetent mouse model. Oncotarget. 2017;8(28):45415–45431. doi: 10.18632/oncotarget.17557
   PubMedGoogle Scholar
• Morales-Molina Á, Gambera S, Cejalvo T, et al. Antitumor virotherapy using syngeneic or allogeneic mesenchymal stem cell carriers induces systemic immune response and intratumoral leukocyte infiltration in mice. Cancer Immunol Immunother CII. 2018;67(10):1589–1602. doi: 10.1007/s00262-018-2220-2
   PubMed Web of Science ®Google Scholar
• Cejalvo T, Perisé-Barrios AJ, Del Portillo I, et al. Remission of spontaneous canine tumors after systemic cellular viroimmunotherapy. Cancer Res. 2018;78(17):4891–4901. doi: 10.1158/0008-5472.CAN-17-3754
   PubMed Web of Science ®Google Scholar
• Martínez-Vélez N, Garcia-Moure M, Marigil M, et al. The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models. Nat Commun. 2019;10(1):2235. doi: 10.1038/s41467-019-10043-0
   PubMedGoogle Scholar
• Tejada S, Alonso M, Patiño A, et al. Phase I trial of DNX-2401 for diffuse intrinsic pontine glioma newly diagnosed in pediatric patients. Neurosurgery. 2018;83(5):1050. doi: 10.1093/neuros/nyx507
   PubMed Web of Science ®Google Scholar
• Rojas JJ, Gimenez-Alejandre M, Gil-Hoyos R, et al. Improved systemic antitumor therapy with oncolytic adenoviruses by replacing the fiber shaft HSG-binding domain with RGD. Gene Ther. 2012;19(4):453–457. doi: 10.1038/gt.2011.106
   PubMed Web of Science ®Google Scholar
• Rojas JJ, Guedan S, Searle PF, et al. Minimal RB-responsive E1A promoter modification to attain potency, selectivity, and transgene-arming capacity in oncolytic adenoviruses. Mol Ther J Am Soc Gene Ther. 2010;18(11):1960–1971. doi: 10.1038/mt.2010.173
   PubMed Web of Science ®Google Scholar
• Rodríguez-García A, Giménez-Alejandre M, Rojas JJ, et al. Safety and efficacy of VCN-01, an oncolytic adenovirus combining fiber HSG-binding domain replacement with RGD and hyaluronidase expression. Clin Cancer Res Off J Am Assoc Cancer Res. 2015;21(6):1406–1418. doi: 10.1158/1078-0432.CCR-14-2213
   PubMed Web of Science ®Google Scholar
• White E. Regulation of the cell cycle and apoptosis by the oncogenes of adenovirus. Oncogene. 2001;20(54):7836–7846. doi: 10.1038/sj.onc.1204861
   PubMed Web of Science ®Google Scholar
• Cuconati A, Degenhardt K, Sundararajan R, et al. Bak and Bax function to limit adenovirus replication through apoptosis induction. J Virol. 2002;76(9):4547–4558. doi: 10.1128/jvi.76.9.4547-4558.2002
   PubMed Web of Science ®Google Scholar
• Leitner S, Sweeney K, Oberg D, et al. Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo. Clin Cancer Res Off J Am Assoc Cancer Res. 2009;15(5):1730–1740. doi: 10.1158/1078-0432.CCR-08-2008
   PubMed Web of Science ®Google Scholar
• Wang H, Satoh M, Chen GP, et al. E1A, E1B double-restricted adenovirus enhances the cytotoxicity and antitumor activity of gemcitabine to renal cell carcinoma. Chin Med J (Engl). 2011;124(7):1082–1087.
   PubMed Web of Science ®Google Scholar
• Tsai YS, Shiau AL, Chen YF, et al. Enhancement of antitumor activity of gammaretrovirus carrying IL-12 gene through genetic modification of envelope targeting HER2 receptor: a promising strategy for bladder cancer therapy. Cancer Gene Ther. 2010;17(1):37–48. doi: 10.1038/cgt.2009.41
   PubMed Web of Science ®Google Scholar
• Roth JC, Cassady KA, Cody JJ, et al. Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing Hil-12, after intracerebral administration to aotus nonhuman primates. Hum Gene Ther Clin Dev. 2014;25(1):16–27. doi: 10.1089/humc.2013.201
   PubMed Web of Science ®Google Scholar
• Pan WY, Lo CH, Chen CC, et al. Cancer immunotherapy using a membrane-bound interleukin-12 with B7-1 transmembrane and cytoplasmic domains. Mol Ther J Am Soc Gene Ther. 2012;20(5):927–937. doi: 10.1038/mt.2012.10
   PubMed Web of Science ®Google Scholar
• Ma W, He H, Wang H. Oncolytic herpes simplex virus and immunotherapy. BMC Immunol. 2018;19(1):40. doi: 10.1186/s12865-018-0281-9
   PubMedGoogle Scholar
• Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14(9):642–662. doi: 10.1038/nrd4663
   PubMed Web of Science ®Google Scholar
• Copeland AM, Newcomb WW, Brown JC. Herpes simplex virus replication: roles of viral proteins and nucleoporins in capsid-nucleus attachment. J Virol. 2009;83(4):1660–1668. doi: 10.1128/JVI.01139-08
   PubMed Web of Science ®Google Scholar
• Kalus P, De Munck J, Vanbellingen S, et al. Oncolytic herpes simplex virus Type 1 induces immunogenic cell death resulting in maturation of BDCA-1+ myeloid dendritic cells. Int J Mol Sci. 2022;23(9):4865. doi: 10.3390/ijms23094865
   PubMed Web of Science ®Google Scholar
• Aldrak N, Alsaab S, Algethami A, et al. Oncolytic herpes simplex virus-based therapies for cancer. Cells. 2021;10(6):1541. doi: 10.3390/cells10061541
   PubMed Web of Science ®Google Scholar
• Gujar SA, Lee PW. Oncolytic virus-mediated reversal of impaired tumor antigen presentation. Front Oncol. 2014;4:77. doi: 10.3389/fonc.2014.00077
   PubMedGoogle Scholar
• Singh PK, Doley J, Kumar GR, et al. Oncolytic viruses & their specific targeting to tumour cells. Indian J Med Res. 2012;136(4):571–584.
   PubMed Web of Science ®Google Scholar
• Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780–2788. doi: 10.1200/JCO.2014.58.3377
   PubMed Web of Science ®Google Scholar
• Cassady KA, Bauer DF, Roth J, et al. Pre-clinical assessment of C134, a chimeric oncolytic herpes simplex virus, in mice and non-human primates. Mol Ther Oncolytics. 2017;5:1–10. doi: 10.1016/j.omto.2017.02.001
   PubMed Web of Science ®Google Scholar
• Todo T, Martuza RL, Rabkin SD, et al. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci U S A. 2001;98(11):6396–6401. doi: 10.1073/pnas.101136398
   PubMed Web of Science ®Google Scholar
• Patel DM, Foreman PM, Nabors LB, et al. Design of a Phase I clinical trial to evaluate M032, a genetically engineered HSV-1 expressing IL-12, in patients with recurrent/progressive glioblastoma multiforme, anaplastic astrocytoma, or gliosarcoma. Hum Gene Ther Clin Dev. 2016;27(2):69–78. doi: 10.1089/humc.2016.031
   PubMed Web of Science ®Google Scholar
• Chiocca EA, Nakashima H, Kasai K, et al. Preclinical toxicology of rQnestin34.5v.2: an oncolytic herpes virus with transcriptional regulation of the ICP34.5 neurovirulence gene. Mol Ther Methods Clin Dev. 2020;17:871–893. doi: 10.1016/j.omtm.2020.03.028
   PubMed Web of Science ®Google Scholar
• Papanastassiou V, Rampling R, Fraser M, et al. The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther. 2002;9(6):398–406. doi: 10.1038/sj.gt.3301664
   PubMed Web of Science ®Google Scholar
• Deng L, Fan J, Ding Y, et al. Oncolytic cancer therapy with a vaccinia virus strain. Oncol Rep. 2019;41(1):686–692. doi: 10.3892/or.2018.6801
   PubMed Web of Science ®Google Scholar
• Guo ZS, Lu B, Guo Z, et al. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. J Immunother Cancer. 2019;7(1):6. doi: 10.1186/s40425-018-0495-7
   PubMedGoogle Scholar
• Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer. 2009;9(1):64–71. doi: 10.1038/nrc2545
   PubMed Web of Science ®Google Scholar
• Parato KA, Breitbach CJ, Le Boeuf F, et al. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther J Am Soc Gene Ther. 2012;20(4):749–758. doi: 10.1038/mt.2011.276
   PubMed Web of Science ®Google Scholar
• Mastrangelo MJ, Maguire HC, Eisenlohr LC, et al. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther. 1999;6(5):409–422. doi: 10.1038/sj.cgt.7700066
   PubMed Web of Science ®Google Scholar
• Park BH, Hwang T, Liu TC, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol. 2008;9(6):533–542. doi: 10.1016/S1470-2045(08)70107-4
   PubMed Web of Science ®Google Scholar
• Breitbach CJ, Burke J, Jonker D, et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature. 2011;477(7362):99–102. doi: 10.1038/nature10358
   PubMed Web of Science ®Google Scholar
• Olland AM, Jané-Valbuena J, Schiff LA, et al. Structure of the reovirus outer capsid and dsRNA-binding protein σ3 at 1.8 Å resolution. Embo J. 2001;20(5):979–989. doi: 10.1093/emboj/20.5.979
   PubMed Web of Science ®Google Scholar
• Urbano P, Urbano FG. The Reoviridae family. Comp Immunol Microbiol Infect Dis. 1994;17(3–4):151–161. doi: 10.1016/0147-9571(94)90040-x
   PubMed Web of Science ®Google Scholar
• Hashiro G, Loh PC, Yau JT. The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch Virol. 1977;54(4):307–315. doi: 10.1007/BF01314776
   PubMed Web of Science ®Google Scholar
• Duncan MR, Stanish SM, Cox DC. Differential sensitivity of normal and transformed human cells to reovirus infection. J Virol. 1978;28(2):444–449. doi: 10.1128/jvi.28.2.444-449.1978
   PubMed Web of Science ®Google Scholar
• Gong J, Mita MM. Activated ras signaling pathways and reovirus oncolysis: an update on the mechanism of preferential reovirus replication in cancer cells. Front Oncol. 2014;4:167. doi: 10.3389/fonc.2014.00167
   PubMedGoogle Scholar
• Müller L, Berkeley R, Barr T, et al. Past, present and future of oncolytic reovirus. Cancers. 2020;12(11):3219. doi: 10.3390/cancers12113219
   PubMed Web of Science ®Google Scholar
• Prestwich RJ, Errington F, Steele LP, et al. Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus. J Immunol Baltim Md 1950. 2009;183(7):4312–4321. doi: 10.4049/jimmunol.0901074
   Google Scholar
• Bos JL. Ras oncogenes in human cancer: a review. Cancer Res. 1989;49(17):4682–4689.
   PubMed Web of Science ®Google Scholar
• Carew JS, Espitia CM, Zhao W, et al. Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer. Cell Death Dis. 2013;4(7):e728. doi: 10.1038/cddis.2013.259
   PubMedGoogle Scholar
• Norman KL, Hirasawa K, Yang AD, et al. Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc Natl Acad Sci U S A. 2004;101(30):11099–11104. doi: 10.1073/pnas.0404310101
   PubMed Web of Science ®Google Scholar
• Gollamudi R, Ghalib MH, Desai KK, et al. Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors. Invest New Drugs. 2010;28(5):641–649. doi: 10.1007/s10637-009-9279-8
   PubMed Web of Science ®Google Scholar
• Comins C, Spicer J, Protheroe A, et al. REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2010;16(22):5564–5572. doi: 10.1158/1078-0432.CCR-10-1233
   PubMed Web of Science ®Google Scholar
• Mehndiratta MM, Mehndiratta P, Pande R. Poliomyelitis: historical facts, epidemiology, and current challenges in eradication. Neurohospitalist. 2014;4(4):223–229. doi: 10.1177/1941874414533352
   PubMedGoogle Scholar
• Mendelsohn CL, Wimmer E, Racaniello VR. Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell. 1989;56(5):855–865. doi: 10.1016/0092-8674(89)90690-9
   PubMed Web of Science ®Google Scholar
• Merrill MK, Bernhardt G, Sampson JH, et al. Poliovirus receptor CD155-targeted oncolysis of glioma. Neuro Oncol. 2004;6(3):208–217. doi: 10.1215/S1152851703000577
   PubMed Web of Science ®Google Scholar
• Desjardins A, Gromeier M, Herndon JE, et al. Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med. 2018;379(2):150–161. doi: 10.1056/NEJMoa1716435
   PubMed Web of Science ®Google Scholar
• Misin A, Antonello RM, Di Bella S, et al. Measles: an overview of a re-emerging disease in children and immunocompromised patients. Microorganisms. 2020;8(2):276. doi: 10.3390/microorganisms8020276
   PubMed Web of Science ®Google Scholar
• de Witte L, Abt M, Schneider-Schaulies S, et al. Measles virus targets DC-SIGN to enhance dendritic cell infection. J Virol. 2006;80(7):3477–3486. doi: 10.1128/JVI.80.7.3477-3486.2006
   PubMed Web of Science ®Google Scholar
• de Vries RD, Lemon K, Ludlow M, et al. In vivo tropism of attenuated and pathogenic measles virus expressing green fluorescent protein in macaques. J Virol. 2010;84(9):4714–4724. doi: 10.1128/JVI.02633-09
   PubMed Web of Science ®Google Scholar
• von Messling V, Svitek N, Cattaneo R. Receptor (SLAM [CD150]) recognition and the V protein sustain swift lymphocyte-based invasion of mucosal tissue and lymphatic organs by a morbillivirus. J Virol. 2006;80(12):6084–6092. doi: 10.1128/JVI.00357-06
   PubMed Web of Science ®Google Scholar
• Fishelson Z, Donin N, Zell S, et al. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCrps) in tumors. Mol Immunol. 2003;40(2–4):109–123. doi: 10.1016/s0161-5890(03)00112-3
   PubMed Web of Science ®Google Scholar
• Anderson BD, Nakamura T, Russell SJ, et al. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res. 2004;64(14):4919–4926. doi: 10.1158/0008-5472.CAN-04-0884
   PubMed Web of Science ®Google Scholar
• Peng KW, TenEyck CJ, Galanis E, et al. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res. 2002;62(16):4656–4662.
   PubMed Web of Science ®Google Scholar
• Galanis E, Atherton PJ, Maurer MJ, et al. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. Cancer Res. 2015;75(1):22–30. doi: 10.1158/0008-5472.CAN-14-2533
   PubMed Web of Science ®Google Scholar
• Reddy PS, Burroughs KD, Hales LM, et al. Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers. J Natl Cancer Inst. 2007;99(21):1623–1633. doi: 10.1093/jnci/djm198
   PubMedGoogle Scholar
• Luo D, Wang H, Wang Q, et al. Senecavirus a as an oncolytic virus: prospects, challenges and development directions. Front Oncol. 2022;12:839536. DOI:10.3389/fonc.2022.839536
   PubMed Web of Science ®Google Scholar
• Rudin CM, Poirier JT, Senzer NN, et al. Phase I clinical study of Seneca valley virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17(4):888–895. doi: 10.1158/1078-0432.CCR-10-1706
   PubMed Web of Science ®Google Scholar
• Moaven O, CW M, JA S, et al. Evolving role of oncolytic virotherapy: challenges and prospects in clinical practice. JCO Precis Oncol. 2021;5(5):432–441. doi: 10.1200/PO.20.00395
   Google Scholar
• Ganesh S, Gonzalez-Edick M, Gibbons D, et al. Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14(12):3933–3941. doi: 10.1158/1078-0432.CCR-07-4732
   PubMed Web of Science ®Google Scholar
• Kaufman HL. Can biomarkers guide oncolytic virus immunotherapy? Clin Cancer Res Off J Am Assoc Cancer Res. 2021;27(12):3278–3279. doi: 10.1158/1078-0432.CCR-21-0660
   PubMed Web of Science ®Google Scholar
• Goradel NH, Baker AT, Arashkia A, et al. Oncolytic virotherapy: challenges and solutions. Curr Probl Cancer. 2021;45(1):100639. doi: 10.1016/j.currproblcancer.2020.100639
   PubMed Web of Science ®Google Scholar
• Chen XT, Dai SY, Zhan Y, et al. Progress of oncolytic virotherapy for neuroblastoma. Front Pediatr. 2022;10:1055729. doi: 10.3389/fped.2022.1055729
   PubMed Web of Science ®Google Scholar